Description Bacterium that causes atypical pneumonia and respiratory tract infections
Structure Mycoplasma pneumoniae is a small, self-replicating bacterium belonging to the family Mycoplasmataceae. Unlike most bacteria, M. pneumoniae lacks a cell wall and is instead surrounded by a sterol-containing cell membrane, making it naturally resistant to beta-lactam antibiotics such as penicillins and cephalosporins. The organism is highly specialized for colonization of the human respiratory tract, where it attaches to ciliated epithelial cells using a specialized attachment organelle. Mycoplasma pneumoniae is one of the smallest free-living organisms capable of independent replication and possesses a highly reduced genome reflecting its dependence on host-derived nutrients. The bacterium is transmitted through respiratory droplets and is a common cause of community-acquired respiratory infections worldwide, particularly among school-aged children, adolescents, and young adults.
Diagnosis The diagnosis of Mycoplasma pneumoniae infection is performed through molecular, serological, and microbiological methods. Polymerase chain reaction (PCR) assays are considered the most sensitive and specific diagnostic tools and allow rapid detection of M. pneumoniae DNA from respiratory specimens. Serological assays, including ELISA-based tests, are commonly used to detect Mycoplasma-specific IgM and IgG antibodies and may assist in the diagnosis of acute or recent infection. Culture of M. pneumoniae is possible using specialized media but is rarely performed in routine clinical practice due to slow growth and technical complexity. Chest radiography may reveal diffuse or patchy infiltrates that are often disproportionate to the severity of clinical symptoms. Laboratory confirmation is particularly useful because clinical findings frequently overlap with those of viral respiratory infections.
Symptoms Mycoplasma pneumoniae infection typically develops following an incubation period of approximately one to four weeks. Common symptoms include persistent dry cough, sore throat, fever, headache, fatigue, and malaise. Respiratory illness often begins gradually and may progress from upper respiratory tract infection to atypical pneumonia characterized by prolonged cough and diffuse pulmonary involvement. Many patients remain ambulatory despite radiographic evidence of pneumonia, leading to the term 'walking pneumonia.' Extrapulmonary manifestations may occur and can include skin rashes, hemolytic anemia, myocarditis, pericarditis, hepatitis, arthritis, and neurological complications such as encephalitis or Guillain-Barré syndrome. Although most infections are self-limiting, severe disease may occur in immunocompromised individuals and patients with underlying respiratory conditions.
Data
FAQ & Publications
Frequently Asked Questions
What is the primary application of the Mycoplasma pneumoniae IgM Control Serum BC127M?
The Mycoplasma pneumoniae IgM Control Serum BC127M is primarily used as an IgM control serum in ELISA assays, specifically compatible with SERION ELISA classic and SERION ELISA antigen assays.
How should the Mycoplasma pneumoniae IgM Control Serum BC127M be stored to maintain its stability?
This control serum should be stored at 2-8°C to ensure proper preservation and maintain its functional integrity for research use.
Is the Mycoplasma pneumoniae IgM Control Serum BC127M species-specific, and what is its target antigen?
Yes, this control serum is reactive specifically to Mycoplasma pneumoniae, targeting the IgM antibodies against this organism for use in infectious disease research.
Publications
pmid
title
authors
citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.